| EPSRC Reference: |
EP/I037172/1 |
| Title: |
Protein-Protein Interaction Inhibitors: From Design and Synthesis, Through Biophysics to Cell Permeable Inhibitors |
| Principal Investigator: |
Klug, Professor DR |
| Other Investigators: |
|
| Researcher Co-Investigators: |
|
| Project Partners: |
|
| Department: |
Chemistry |
| Organisation: |
Imperial College London |
| Scheme: |
Standard Research |
| Starts: |
01 April 2011 |
Ends: |
30 September 2013 |
Value (£): |
107,349
|
| EPSRC Research Topic Classifications: |
| Biological & Medicinal Chem. |
|
|
| EPSRC Industrial Sector Classifications: |
| Pharmaceuticals and Biotechnology |
|
|
| Related Grants: |
|
| Panel History: |
| Panel Date | Panel Name | Outcome |
|
21 Feb 2011
|
ChemBio Collaborative Networks
|
Announced
|
|
|
Summary on Grant Application Form |
|
The development of new medicines relies upon the ability of scientists to understand the biological details of a disease and also the way in which new molecular medicines can be designed to either cure the illness or alleviate its symptoms. One very important biological mechanism is the way in which one protein recognises and binds to another protein in order to regulate its function. This functional regulation by protein-protein interactions underpins most of the biological activity in living cells, and yet we do not understand what properties of a protein allow it to bind to another, nor do we understand how to design molecules to prevent or enhance such interactions. Gaining such an understanding would be a huge advance. It is estimated that there are approximately 650,000 types of specific protein-protein interactions in each human cell. This means that there are potentially 650,000 targets for modifying biological function by the use of drugs. Essentially every part of the biological process, and therefore every disease, could in principle be addressed by such drugs. Although the knowledge of how to do this remains beyond our grasp, progress has been made in some parts of the problem, and new ways of looking at the problem have also been developed with others already in development. This research network has the aim of bringing the whole UK community engaged in this type of research together, and in particular connecting the scientists in universities and research institutes with the scientists in biotechnology and pharmaceutical companies to pool their intellectual and technical capabilities. In doing this we have two main aims in mind. Firstly the sharing of knowledge so that everyone has a wider picture of what is now possible and understood and what still needs to be learned and discovered. Secondly the formulation of a UK-wide plan to solve the outstanding problems in this area with the intention of accelerating the development of new drugs for serious illnesses by connecting together progress made by the various research teams across the UK.
|
|
Key Findings |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Potential use in non-academic contexts |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
|
Impacts |
|
| Description |
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk |
| Summary |
|
| Date Materialised |
|
|
|
|
Sectors submitted by the Researcher |
|
This information can now be found on Gateway to Research (GtR) http://gtr.rcuk.ac.uk
|
| Project URL: |
http://sdrv.ms/14VxeBG |
| Further Information: |
|
| Organisation Website: |
http://www.imperial.ac.uk |